Canadian Cardiovascular Society Position Statement onFamilial Hypercholesterolemia

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages 1471-1481

  Genest, Jacques ^a   Hegele, Robert A ^b   Bergeron, Jean ^c   Brophy, James ^a   Carpentier, Andre ^d   Couture, Patrick ^b   Davignon, Jean ^e   Dufour, Robert ^e   Frohlich, Jiri ^f   Gaudet, Daniel ^g   Gupta, Milan ^h,i   Krisnamoorthy, Preetha ^a   Mancini, John ^e   McCrindle, Brian ⁱ   Raggi, Paolo ^j   Ruel, Isabelle ^a   St Pierre, Julie ^d,k  

^a MCGILL UNIVERSITY   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k CHICOUTIMI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; RESIN;

ALGORITHM; APHERESIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CANADIAN; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTRACEPTION; DIET THERAPY; EARLY DIAGNOSIS; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FATTY LIVER; GENE MUTATION; HEALTH CARE; HEALTH CARE PERSONNEL; HOMOZYGOTE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLASMAPHERESIS; PRACTICE GUIDELINE; PREGNANCY; PRIMARY PREVENTION; SCREENING; CANADA; CARDIOVASCULAR DISEASES; COMPLICATION; EPIDEMIOLOGY; GENETICS; HEALTH PROMOTION; HYPERLIPOPROTEINEMIA TYPE II; MORBIDITY; SURVIVAL RATE; TRENDS;

CANADA; CARDIOVASCULAR DISEASES; HEALTH PROMOTION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MORBIDITY; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84919769680     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.028     Document Type: Article

References (70)

1. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490a.
2. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. JClin Lipidol 2011, 5:S1-S8.
3. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. JClin Endocrinol Metab 2012, 97:3956-3964.
4. Goldstein J.L., Hazzard W.R., Schrott H.G., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. JClin Invest 1973, 52:1533-1543.
5. Do R, Stitziel NO, Won HH, etal. A rare variant association study with exome sequencing in > 9,700 early-onset myocardial infarction cases and controls. Nature, in press.
6. Moorjani S., Roy M., Gagne C., et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec province. Arteriosclerosis 1989, 9:211-216.
7. Sjouke B, Kusters DM, Kindt I, etal. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome [e-pub ahead of print]. Eur Heart J , accessed October 30, 2014. doi:10.1093/eurheartj/ehu058.
8. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists Collaborators.
9. Versmissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008, 337:a2423.
10. Yuan G., Wang J., Hegele R.A. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006, 174:1124-1129.
11. Marks D., Thorogood M., Neil H.A., Humphries S.E. Areview on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168:1-14.
12. Fouchier S.W., Defesche J.C., Umans-Eckenhausen M.W., Kastelein J.P. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001, 109:602-615.
13. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
14. Futema M., Whittall R.A., Kiley A., et al. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013, 229:161-168.
15. World Health Organization, Familial Hypercholesterolemia. Report of the second WHO consultation 1999, World Health Organization, Geneva.
16. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
17. Newman T., Pletcher M., Hulley S. Overly aggressive new guidelines for lipid and lipoprotein screening in children: evidence of a broken process. Pediatrics 2012, 130:349-352.
18. McCrindle B.W., Kwiterovich P.O., McBride P.E., Daniels S.R., Kavey R.E. Guidelines for lipid screening in children and adolescents: bringing evidence to the debate. Pediatrics 2012, 130:353-356.
19. McCrindle B.W., Kwiterovich P.O., McBride P.E., Daniels S.R., Kavey R.E. Author's response. Universal lipid screening: in response to ongoing debate. Pediatrics 2013, 131:e1387-e1388.
20. Dixon D.B., Kornblum A.P., Steffen L.M., Zhou X., Steinberger J. Implementation of lipid screening guidelines in children by primary pediatric providers. JPediatr 2014, 164:572-576.
21. Laitinen T.T., Pahkala K., Magnussen C.G., et al. Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: tThe cardiovascular risk in young Finns study. Circulation 2012, 125:1971-1978.
22. de Jongh S., Lilien M.R., op't Roodt J., et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. JAm Coll Cardiol 2002, 40:2117-2121.
23. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004, 292:331-337.
24. Rodenburg J., Vissers M.N., Wiegman A., et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007, 116:664-668.
25. Gillman M.W. Screening for familial hypercholesterolemia in childhood. Am J Dis Child 1993, 147:393-396.
26. Gillman M.W. Changing the conversation regarding pediatric cholesterol screening: the rare disease paradigm. Arch Pediatr Adolesc Med 2012, 166:1097-1098.
27. Harris W.S., Mozaffarian D., Rimm E., et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association nutrition subcommittee of the council on nutrition, physical activity, and metabolism; council on cardiovascular nursing; and council on epidemiology and prevention. Circulation 2009, 119:902-907.
28. Dietary reference intakes tables, Health Canada. Available at: . Accessed August 31,2012. http://www.hc-sc.gc.ca/fn-an/nutrition/reference/table/index-eng.
29. Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian working group consensus conference. Can J Cardiol 2011, 27:635-662.
30. Mancini G.B., Tashakkor A.Y., Baker S., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Can J Cardiol 2013, 29:1553-1568.
31. Naci H., Brugts J., Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013, 6:390-399.
32. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. JAm Coll Cardiol 2011, 57:1535-1545.
33. O'Gorman C.S., Higgins M.F., O'Neill M.B. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol 2009, 30:482-489.
34. Arambepola C., Farmer A.J., Perera R., Neil H.A. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2007, 195:339-347.
35. Avis H.J., Vissers M.N., Stein E.A., et al. Asystematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007, 27:1803-1810.
36. Watts G.F., Gidding S., Wierzbicki A.S., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014, 171:309-325.
37. Cuchel M., Meagher E.A., du Toit T.H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
38. Raal F.J., Santos R.D., Blom D.J., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
39. Rader D.J., deGoma E.M. Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 2014, 65:385-403.
40. Stein E.A. Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr Opin Lipidol 2013, 24:510-517.
41. Berenson G.S., Srinivasan S.R., Bao W., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study. NEngl J Med 1998, 338:1650-1656.
42. McGill H.C., McMahan C.A., Zieske A.W., et al. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001, 103:1546-1550.
43. Raitakari O.T., Juonala M., Kahonen M., et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA 2003, 290:2277-2283.
44. Davis P.H., Dawson J.D., Riley W.A., Lauer R.M. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation 2001, 104:2815-2819.
45. Mabuchi H., Koizumi J., Shimizu M., Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989, 79:225-232.
46. Mouratidis B., Vaughan-Neil E.F., Gilday D.L., et al. Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning. Am J Cardiol 1992, 70:1109-1112.
47. Hamilton-Craig I., Kostner K., Colquhoun D., Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010, 6:1023-1037.
48. Schuff-Werner P., Fenger S., Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 2012, 7:7-14.
49. McCrindle B.W., American Heart Association Writing Group, Urbina E.M., et al. Summary of the American Heart Association's scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol 2007, 27:982-985.
50. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: Data in 2400 patients. JIntern Med 2004, 256:482-490.
51. Oosterveer D.M., Versmissen J., Schinkel A.F., et al. Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. Clin Lipidol 2010, 5:189-197.
52. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
53. Thanassoulis G., Campbell C.Y., Owens D.S., et al. Genetic associations with valvular calcification and aortic stenosis. NEngl J Med 2013, 368:503-512.
54. Michos E.D., Nasir K., Rumberger J.A., et al. Relation of family history of premature coronary heart disease and metabolic risk factors to risk of coronary arterial calcium in asymptomatic subjects. Am J Cardiol 2005, 95:655-657.
55. Clarke R.E., Padayachee S.T., Preston R., et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013, 99:175-180.
56. Descamps O.S., de Meester A., Cheron P., Kastelein J.J., Heller F.R. Silent ischaemia in familial hypercholesterolemia. Atheroscler Suppl 2003, 4:7-8.
57. Cuchel M., Bruckert E., Ginsberg H.N., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014, 35:2146-2157.
58. Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J. National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid association expert panel on familial hypercholesterolemia. JClin Lipidol 2011, 5:S9-S17.
59. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255. HEART-UK LDL Apheresis Working Group.
60. Kolansky D.M., Cuchel M., Clark B.J., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1438-1443.
61. Sachais B.S., Katz J., Ross J., Rader D.J. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. JClin Apheresis 2005, 20:252-255.
62. Raal F.J., Pilcher G.J., Panz V.R., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
63. Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013, 14:19-27.
64. Thompson G.R. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl 2013, 14:67-70.
65. Awan Z., Alrasadi K., Francis G.A., et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008, 28:777-785.
66. Edison R.J., Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004, 131:287-298.
67. Cashin-Hemphill L., Noone M., Abbott J.F., Waksmonski C.A., Lees R.S. Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000, 86:1160. A10.
68. Umans-Eckenhausen M.A., Defesche J.C., Sijbrands E.J., Scheerder R.L., Kastelein J.J. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001, 357:165-168.
69. Marks D., Wonderling D., Thorogood M., et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002, 324:1303.
70. NICE. National Institute for Health and Care Excellence. Identification and management of familial hypercholesterolaemia. Available at: . Accessed August 28, 2014. http://www.nice.org.uk/CG071.